PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
9469593-6	1998	Interestingly, Chol did not affect the lipolysis rates even though it decreased TG solubility and apoC-II binding.	Cholesterol	15-19	apolipoprotein C2	Homo sapiens	98-105	
19729871-6	2009	CONCLUSION: The particle size of HDL become smaller with the increase of apoCII levels, implying that the efficiency of reverse cholesterol transport (RCT) was impaired and blocked the maturation of HDL.	Cholesterol	128-139	apolipoprotein C2	Homo sapiens	73-79	
11162594-3	2001	ApoA-I and all of the other exchangeable apolipoproteins tested (apoA-II, apoA-IV, apoC-I, apoC-II, apoC-III, apoE) showed greater than a threefold increase in cholesterol and phospholipid efflux from ABCAI-GFP transfected cells compared to control cells.	Cholesterol	160-171	apolipoprotein C2	Homo sapiens	91-98	
10972686-12	2000	Multivariate analysis suggested that the relative lack of apoCII and apoCIII on patients VLDL1 was related to smaller particle size and increased free cholesterol:phospholipid (FC:PL) ratio.	Cholesterol	151-162	apolipoprotein C2	Homo sapiens	58-64	
1452137-7	1992	There was a significantly positive correlation between TC and apoAI, CII, CIII in HDL respectively, which indicated that apoCII and CIII were also associated with the alteration of HDL cholesterol.	Cholesterol	185-196	apolipoprotein C2	Homo sapiens	121-127	
1797121-6	1991	HDL cholesterol was not inversely correlated with triglycerides, and showed a highly positive correlation with apo E, apo CII and apo CIII, which did not correlate with HDL cholesterol in adults.	Cholesterol	4-15	apolipoprotein C2	Homo sapiens	118-125	
1525253-11	1992	Furthermore, in male coronary heart disease patients a negative correlation was found between the concentrations of apolipoprotein CII/CIII-B and HDL-cholesterol.	Cholesterol	150-161	apolipoprotein C2	Homo sapiens	116-134	
2600540-4	1989	In the present study, we have investigated the effect of the apoC-II polymorphism on quantitative serum levels of total cholesterol, total high density lipoprotein (HDL) cholesterol, cholesterol in high density lipoprotein subfractions, low density lipoprotein (LDL) cholesterol, and triglycerides (TG) in a sample of 368 unrelated Nigerian blacks.	Cholesterol	120-131	apolipoprotein C2	Homo sapiens	61-68	
34458211-10	2021	Plasma levels of apoC-II and apoC-III were positively correlated with total cholesterol, triglyceride, and low-density lipoprotein (LDL) (all p < 0.001).	Cholesterol	76-87	apolipoprotein C2	Homo sapiens	17-24	
2600540-6	1989	In males, the effect of the APOC-II*2 allele was to lower the total serum cholesterol and LDL-cholesterol levels by 13.28 mg/dl and 10.55 mg/dl, respectively, relative to the common allele, APOC-II*1.	Cholesterol	74-85	apolipoprotein C2	Homo sapiens	28-35	
2600540-6	1989	In males, the effect of the APOC-II*2 allele was to lower the total serum cholesterol and LDL-cholesterol levels by 13.28 mg/dl and 10.55 mg/dl, respectively, relative to the common allele, APOC-II*1.	Cholesterol	94-105	apolipoprotein C2	Homo sapiens	28-35	
3411241-2	1988	We have determined concentrations of apoC-II and apoC-III in VLDL and HDL in subjects with a wide range of VLDL triglyceride and HDL cholesterol levels, and correlated these levels with fractional catabolic rates (FCR) of VLDL triglyceride and HDL apolipoprotein A-I (apoA-I).	Cholesterol	133-144	apolipoprotein C2	Homo sapiens	37-44	
6433686-5	1984	Controlling for Apo C-II reduced the black-white differences in total cholesterol 87%, LDL cholesterol 44%, VLDL cholesterol 83%, and total triglyceride 83%.	Cholesterol	70-81	apolipoprotein C2	Homo sapiens	16-24	
6433686-5	1984	Controlling for Apo C-II reduced the black-white differences in total cholesterol 87%, LDL cholesterol 44%, VLDL cholesterol 83%, and total triglyceride 83%.	Cholesterol	91-102	apolipoprotein C2	Homo sapiens	16-24	
6433686-5	1984	Controlling for Apo C-II reduced the black-white differences in total cholesterol 87%, LDL cholesterol 44%, VLDL cholesterol 83%, and total triglyceride 83%.	Cholesterol	91-102	apolipoprotein C2	Homo sapiens	16-24	
23119086-9	2012	Finally, we present strong evidence for epistasis (P-value for interaction =  0.0006 in GOLDN, 0.05 in HyperTG) between rs10401969 near CILP2 and rs4420638 in the APOE-APOC1-APOC4-APOC2 cluster with total cholesterol response to fenofibrate.	Cholesterol	205-216	apolipoprotein C2	Homo sapiens	180-185